This study is testing a drug called HH2853 in people with certain types of lymphoma (FL Lymphoma, Peripheral T Cell Lymphoma) and advanced solid tumors. The main goals are to find the safest and most effective dose of HH2853, and to understand any side effects. HH2853 is given as tablets twice a day. The study is open to adults aged 18 and older. It's a multi-part study, starting with finding the right dose and then expanding to learn more about how well it works and its safety. The study aims to enroll 254 participants, but its current status is unclear.

Study design

This is an open-label (meaning everyone knows what treatment is being given), multi-center, first-in-human study with three parts: dose escalation, dose extension, and Phase II. It plans to enroll 254 participants.

What's involved

You would take HH2853 tablets twice daily in continuous 28-day treatment cycles. Safety and side effects will be checked during these cycles.

Compensation

Not stated in the trial record.

Follow-up

Safety and dose-related outcomes are measured during 28-day treatment cycles.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.